JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
The transaction is expected to close in the first quarter of 2022
The brand is now available pan-India through their distribution partner
It is the generic version of molnupiravir
The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed potent Omicron pseudovirus neutralization function
It has also been granted permission to conduct trials for booster dose
The virtual world makes it possible to visualize, test, understand and predict what cannot be seen, before a patient is treated
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
Doxycycline Hyclate Delayed Release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria
Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.
Subscribe To Our Newsletter & Stay Updated
